Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer
European urology.
2024 Sep ;
86 (3) :
280.
[epub] 20240409
Language English Country Switzerland Media print-electronic
Document type Letter, Journal Article
Persistent link
https://www.medvik.cz/link/pmid38599993
PubMed
38599993
DOI
10.1016/j.eururo.2024.03.034
PII: S0302-2838(24)02262-0
Knihovny.cz E-resources
- MeSH
- Adjuvants, Immunologic therapeutic use adverse effects MeSH
- BCG Vaccine * therapeutic use adverse effects MeSH
- Quinoxalines therapeutic use MeSH
- Neoplasm Invasiveness MeSH
- Humans MeSH
- Non-Muscle Invasive Bladder Neoplasms MeSH
- Urinary Bladder Neoplasms * drug therapy pathology MeSH
- Pyrazoles * therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Letter MeSH
- Names of Substances
- Adjuvants, Immunologic MeSH
- BCG Vaccine * MeSH
- Quinoxalines MeSH
- erdafitinib MeSH Browser
- Pyrazoles * MeSH
References provided by Crossref.org
